BioStock: BioStock launches Consensus Analysis – a new analytical format for Nordic life science
Idag, 11:06
BioStock today announces the launch of Consensus Analysis, a new editorial format that aggregates and interprets analyst panel views on listed life science companies around quarterly earnings. The inaugural edition focuses on Novo Nordisk.
Published today, on 19 May 2026, the first instalment maps 19 analyst houses covering Novo Nordisk, with share price targets ranging from DKK 175 (Bernstein, Sell) to DKK 440 (SEB, Buy). The format breaks the consensus picture into its constituent parts: recommendation distribution, the catalysts driving panel revisions, and the key signals that investors should monitor going forward.
The launch edition identifies three material observations. Fifteen of the nineteen share price targets pre-date the Novo Nordisk's Q1 report of 6 May, suggesting that consensus has further to travel if the four post-print houses – averaging DKK 329 – are indicative.
Every Buy rating in the panel originates from a Nordic or European house, averaging DKK 372, whilst the seven US houses converge on an average of DKK 247. That translates into a DKK 125 gap that ranks among the widest seen in large-cap European pharma in years. Meanwhile, Novo Nordisk trades at 10.5 times trailing earnings against Eli Lilly's approximately 36 times – the widest relative valuation spread between the two GLP-1 giants in over five years.
The Novo Nordisk Consensus Analysis is available at biostock.se, and equivalent analyses will be published in connection with quarterly earnings seasons for selected companies going forward.
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
BioStock: BioStock launches Consensus Analysis – a new analytical format for Nordic life science
Idag, 11:06
BioStock today announces the launch of Consensus Analysis, a new editorial format that aggregates and interprets analyst panel views on listed life science companies around quarterly earnings. The inaugural edition focuses on Novo Nordisk.
Published today, on 19 May 2026, the first instalment maps 19 analyst houses covering Novo Nordisk, with share price targets ranging from DKK 175 (Bernstein, Sell) to DKK 440 (SEB, Buy). The format breaks the consensus picture into its constituent parts: recommendation distribution, the catalysts driving panel revisions, and the key signals that investors should monitor going forward.
The launch edition identifies three material observations. Fifteen of the nineteen share price targets pre-date the Novo Nordisk's Q1 report of 6 May, suggesting that consensus has further to travel if the four post-print houses – averaging DKK 329 – are indicative.
Every Buy rating in the panel originates from a Nordic or European house, averaging DKK 372, whilst the seven US houses converge on an average of DKK 247. That translates into a DKK 125 gap that ranks among the widest seen in large-cap European pharma in years. Meanwhile, Novo Nordisk trades at 10.5 times trailing earnings against Eli Lilly's approximately 36 times – the widest relative valuation spread between the two GLP-1 giants in over five years.
The Novo Nordisk Consensus Analysis is available at biostock.se, and equivalent analyses will be published in connection with quarterly earnings seasons for selected companies going forward.
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Evolution
Evolution
Marknadsöversikt
1 DAG %
Senast
1 mån
